Protagonist Therapeutics, Inc.

Healthcare

NASDAQ:PTGX · NASDAQ Global Market

Market Cap $7.10B Beta 1.83 P/E (TTM) -62.4

$109.78 +0.17%

+$0.19 today

52W Low $49.38High $111.78

Vol 0.44M · Avg 0.73M

EPS (TTM)-$1.76

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+94.75%

Period High

$110.06

Period Low

$49.70

Latest

$109.78

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

TG Therapeutics, Inc.

NASDAQ:TGTX

$7.59B

Alkermes plc

NASDAQ:ALKS

$7.43B

Kymera Therapeutics, Inc.

NASDAQ:KYMR

$7.01B

Immunovant, Inc.

NASDAQ:IMVT

$6.93B

Arcellx, Inc.

ACLX

$6.73B

PTC Therapeutics, Inc.

NASDAQ:PTCT

$6.23B

Akero Therapeutics, Inc.

AKRO

$4.50B

Crinetics Pharmaceuticals, Inc.

NASDAQ:CRNX

$3.69B

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

$3.56B

Viking Therapeutics, Inc.

NASDAQ:VKTX

$3.36B

What is the latest PTGX filing?

The latest filing shown is 4 dated Jun 11, 2026.

How many recent filings does PTGX have?

Intrinsic Alpha currently shows 20 recent filings for PTGX.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.